Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.
See the Cosentyx dosing schedule and summary of product characteristics.
PsA, AS and nr-axSpA dosing: a convenient dosing schedule that delivers all the benefits of Cosentyx1
Cosentyx, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
*PsA patients initiated on 150 mg can be increased to 300 mg based on clinical response.
†Individual patient dosing may vary - please consult the Prescribing Information for full details.
Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
For patients with active AS, the recommended dose is 150 mg by subcutaneous injection. AS patients initiated on 150 mg can be increased to 300 mg based on clinical response.
Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.
For patients with active nr-axSpA, the recommended dose is 150 mg by subcutaneous injection.
Starting a patient on Cosentyx?
To make the patient’s experience as good as possible, we have a range of resources for you to use with your Cosentyx patients.
Explore our repository of resources, which includes a Cosentyx injection demonstration video, patient information leaflets, a digital dosing schedule and more.
More product information
Summary of product characteristics for Cosentyx
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
AS, ankylosing spondylitis; CRP, C-reactive protein, DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; SC, subcutaneous; TNF, tumour necrosis factor-alpha.
Reference
- Cosentyx Summary of Product Characteristics.